Literature DB >> 20019149

Fluctuations in phenotypes and genotypes within populations of Pseudomonas aeruginosa in the cystic fibrosis lung during pulmonary exacerbations.

Joanne L Fothergill1,2, Eilidh Mowat1, Martin J Ledson3, Martin J Walshaw3, Craig Winstanley1,2.   

Abstract

Chronic respiratory infection by Pseudomonas aeruginosa contributes significantly to the morbidity and mortality associated with cystic fibrosis (CF). Using a series of phenotypic and genotypic tests on collections of 40 isolates per sputum sample, we analysed fluctuations within sputum populations of the P. aeruginosa Liverpool epidemic strain (LES) during pulmonary exacerbations. For each of three patients, three sequential sputum samples were analysed: (1) on presentation with exacerbation at the Regional Adult Cystic Fibrosis Unit, Liverpool; (2) a few days into intravenous antibiotic treatment; (3) when the patient had recovered. Fluctuations were observed in morphotype distribution, the production of virulence-associated quorum-sensing-dependent exoproducts (the phenazine compound pyocyanin and the elastase LasA), antibiotic susceptibility profiles and levels of auxotrophy. PCR assays were used to screen isolates for the presence of novel regions of the LES genome (islands and prophages) and to detect free phages. In one patient there was an increase in the prevalence of the LESGI-5 genomic island during the sampling period from 10 to 97.5 % carriage. LES phages 2-4 were detected in either the majority or all sputum samples tested, indicating widespread phage activity during the sampling period. The results of this study are indicative that significant fluctuations occur within P. aeruginosa populations during short periods of pulmonary exacerbation and intravenous antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20019149     DOI: 10.1099/jmm.0.015875-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  47 in total

Review 1.  Detecting genomic islands using bioinformatics approaches.

Authors:  Morgan G I Langille; William W L Hsiao; Fiona S L Brinkman
Journal:  Nat Rev Microbiol       Date:  2010-05       Impact factor: 60.633

2.  Effect of antibiotic treatment on bacteriophage production by a cystic fibrosis epidemic strain of Pseudomonas aeruginosa.

Authors:  Joanne L Fothergill; Eilidh Mowat; Martin J Walshaw; Martin J Ledson; Chloe E James; Craig Winstanley
Journal:  Antimicrob Agents Chemother       Date:  2010-10-25       Impact factor: 5.191

Review 3.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

4.  Lytic phages obscure the cost of antibiotic resistance in Escherichia coli.

Authors:  Samuel J Tazzyman; Alex R Hall
Journal:  ISME J       Date:  2015-03-17       Impact factor: 10.302

Review 5.  Is There Potential for Repurposing Statins as Novel Antimicrobials?

Authors:  Emma Hennessy; Claire Adams; F Jerry Reen; Fergal O'Gara
Journal:  Antimicrob Agents Chemother       Date:  2016-08-22       Impact factor: 5.191

6.  Methods for Extraction and Detection of Pf Bacteriophage DNA from the Sputum of Patients with Cystic Fibrosis.

Authors:  Elizabeth B Burgener; Patrick R Secor; Michael C Tracy; Johanna M Sweere; Elisabeth M Bik; Carlos E Milla; Paul L Bollyky
Journal:  Phage (New Rochelle)       Date:  2020-06-16

Review 7.  Pharmacokinetics and pharmacodynamics of aerosolized antibacterial agents in chronically infected cystic fibrosis patients.

Authors:  Axel Dalhoff
Journal:  Clin Microbiol Rev       Date:  2014-10       Impact factor: 26.132

8.  Rapid diversification of Pseudomonas aeruginosa in cystic fibrosis lung-like conditions.

Authors:  Alana Schick; Rees Kassen
Journal:  Proc Natl Acad Sci U S A       Date:  2018-10-01       Impact factor: 11.205

Review 9.  Pseudomonas aeruginosa adaptation and evolution in patients with cystic fibrosis.

Authors:  Elio Rossi; Ruggero La Rosa; Jennifer A Bartell; Rasmus L Marvig; Janus A J Haagensen; Lea M Sommer; Søren Molin; Helle Krogh Johansen
Journal:  Nat Rev Microbiol       Date:  2020-11-19       Impact factor: 60.633

Review 10.  Fluoroquinolones in the treatment of bronchopulmonary disease in cystic fibrosis.

Authors:  Matthew Hurley; Alan Smyth
Journal:  Ther Adv Respir Dis       Date:  2012-09-11       Impact factor: 4.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.